2 Min.
"Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer Oncology Times Broadcast News
-
- Wissenschaft
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1.
She discussed her team’s findings with Peter Goodwin.
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1.
She discussed her team’s findings with Peter Goodwin.
2 Min.